Erectile Dysfunction: Serious Research for a Serious Problem

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health. FIRST IN LINE: Viagra is actually the second drug approved t

| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health.

By the end of the second quarter of 1998, Viagra sales accounted for more than $400 million of the company's $1 billion increase in total revenues compared to 1997. And by mid-August, 30 million pills had been dispensed. These figures reflect mainly domestic sales--38 other countries have now approved Viagra, including the 15 nations of the European Union, with 41 more expected by year's end. Financial analysts project a worldwide market ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Barry Palevitz

    This person does not yet have a bio.
  • Ricki Lewis

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio